Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × forodesine × Clear all
NCT00289549 2012-02-08

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

Phase 2 Completed
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00501735 2012-01-23

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Phase 2 Completed
144 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00095381 2012-01-19

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

BioCryst Pharmaceuticals

Phase 2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡